Mr Matthew Dudek
Acting Chief Executive Officer
Originally from a chartered accounting background – KPMG (audit and assurance), Matthew has held numerous financial reporting and operational positions within a variety of large listed and unlisted multinational businesses including Toll Holdings Limited, TNT Australia and Burns Philp Limited.
In Matthew’s previous roles he has delivered improvements to business processes designed to enhance both internal and statutory reporting as well as strengthen internal control frameworks. He has been involved in developing business strategies, responsible for developing complex budgeting, consolidation of financial results and ensuring tax and regulatory compliance for international businesses.
Matthew is a member of Chartered Accountants in Australia and New Zealand (CA ANZ).
Mr Sandy Beard
Sandy was appointed Chair of Anagenics Limited on 15 February 2022. He has been a Director of numerous public and private companies over the past 25 years. He is the former Chief Executive Officer of CVC Limited (ASX: CVC) (between 2000-2019) where he oversaw annual shareholder returns in excess of 15% per annum. He has extensive experience with investee businesses, including providing advice, assisting in acquisitions, divestments and capital raisings, and in direct management roles, especially bringing management expertise to small-cap companies and driving shareholder returns.
Sandy is currently chair of Hancock & Gore (ASX: HNG), FOS Capital (ASX: FOS) and a director of Centrepoint Alliance (ASX: CAF) and Pure Foods Tasmania (ASX: PFT).
Dr Martin Cross
Dr Cross is a highly regarded pharmaceutical executive with over 30 years’ experience including corporate and industry leadership roles directly influencing healthcare policy and government legislation in Australia and global business management, marketing and sales roles.
From 2013 to 2015, Dr Cross was Chairman of Medicines Australia, the country’s peak body representing the research based pharmaceutical industry in Australia. Prior to leading Medicines Australia, from 2010 to 2013 Dr Cross was Chairman of both the Generics Medicine Industry Association and Pharmaceutical Industry Council. During this time, Dr Cross was also Managing Director of Alphapharm in Australia and New Zealand, with responsibility for 750 employees and sales of over US $500m per annum.
From 2003 to 2008, Dr Cross was Country Head and Managing Director of Novartis Australia and New Zealand, and Head of Global Marketing and Sales Capabilities from 2001 to 2003, based in Switzerland.
Mr Dennis Eck
Mr Dennis Eck brings 40 years’ senior management experience in the retail sector to Cellmid’s board, providing significant strategic and operational expertise. Mr Eck, a professional investor, has extensive retail experience, from fashion to groceries, including cosmetics and hair salons. As a senior strategist, Mr Eck has helped reshape the operations of several retail businesses delivering outstanding shareholder returns. Mr. Eck served as the Chief Executive Officer of Coles Myer Ltd. from November 1997 to September 2001 following his service in a number of positions including as Chief operating officer of Coles Myer Ltd and Managing director of Coles Myer Supermarkets. Mr Eck’s outstanding successes at Coles were recognised by the Association of Chartered Accountants when, in 2001, he was named the Astute Business Leader of the Year in Australia. Recently, Mr Eck served as an Interim Chief Executive Officer at Ulta Beauty, and currently holds a position as Board Member at that Company.
Mr Phillip Christopher
Phillip Christopher has over 12 years of experience across private equity, M&A and capital markets. He has led a broad range of strategic investments throughout his career and provided board level support, corporate and commercial advice to investee companies.
Phillip is Investment Director of Hancock & Gore Limited (ASX:HNG) where he has been responsible for private investments, including BLC Cosmetics, prior to its merger with Cellmid. Phillip also spent six years at Alceon Group where he was a Director in the Private Equity team, which has made significant investments in e-commerce and branded products businesses. Prior to that he was a member of the Investment Banking division of Goldman Sachs.
Phillip is a Director of Pegasus Healthcare and HGL Investments and was previously an Alternate Director of Marlin Brands.
Mr Scott Greasley
Scott Greasley has over 15 years experience across retail, ecommerce and wholesale within the branded consumer segment. He led successful teams transforming underperforming markets across APAC, Asia and the Middle East into highly profitable regions. Scott’s key offering is identifying and building market-leading consumer businesses that deliver significant EBITDA growth, with minimal investment. Scott has experience working in both private equity and ASX-listed environments.
As Executive Director of Anagenics, Scott is leading the growth and expansion of the business via M&A activity whilst supporting day to day operations with the management team. Prior to this appointment, Scott was Head of Greater China & Emerging Markets for Boardriders Inc based in Hong Kong, where he led the transformation of the China marketplace developing a strategic plan for the group across the region. He’s also spent time with the Billabong Group in Singapore and Australia, operating across all verticals of the business.
Dr Dominic Burg
Chief Operating Officer
Dr Dominic Burg is an experienced scientist and an accomplished science communicator with a background in large multi-national projects in translational medicine. Dominic has successfully transitioned his analytical and operational skillset towards directing the day to day operations, logistics, manufacture, HR and regulatory affairs of Anagenics. Dominic is also responsible for scientific and technical aspects of new product development as well as science communications.
Dominic undertook his PhD studies at the University of NSW School of Biotechnology and Biomolecular Sciences and underwent post doctoral training at the University of Sydney, studying the systems biology of complex inflammatory processes underpinning cancer cachexia syndrome. Dominic was subsequently recruited to the UK to work as a post doctoral fellow in the large multinational public-private research consortium UBIOPRED as the proteomics workstream leader. It was during this time that Dominic honed his analytical capabilities, science communications, project management skills and strategic thinking, as well as developing a passion for fostering multidisciplinary collaboration.
Ms Carolyn Heath
Chief Customer Officer
Carolyn Heath has over 25 years’ experience within marketing, sales, and business development, working across local and international brands in the health, beauty and consumer goods categories. She was responsible for the management of brands such as Dr LeWinn’s and Akin (McPherson’s), Tommee Tippee (Jackel), Continental (Unilever), Max Factor (P&G), and Johnson & Johnson’s suncare range. For the last 7 years Carolyn led the housewares marketing team at McPherson’s, implemented ecommerce across the business and was Head of International Sales and Export. Her key achievement at McPherson’s was the development and execution of their China strategy for Akin (haircare) and Dr LeWinn’s (skincare), delivering an incremental $12m in revenue for the first 15 months of launch.